The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per 4.00 response:

1. Issuer's Identity

**CIK (Filer ID Number)** 

**Previous** X None Names

**Entity Type** 

0001637715

Name of Issuer

X Corporation Limited Partnership

Reneo Pharmaceuticals, Inc.

Limited Liability Company

Jurisdiction of Incorporation/Organization

General Partnership **Business Trust** 

**DELAWARE** 

Other (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Reneo Pharmaceuticals, Inc.

**Street Address 1** 

**Street Address 2** 

12230 El Camino Real, Suite 230

City

State/Province/Country

ZIP/PostalCode

**Phone Number of Issuer** 

San Diego

**CALIFORNIA** 

92130

858-283-0280

3. Related Persons

**Last Name** 

First Name

Middle Name

Flesher

Gregory

**Street Address 1** 

**Street Address 2** 

12230 El Camino Real, Suite 230

City

**State/Province/Country** 

ZIP/PostalCode

San Diego

**CALIFORNIA** 

92130

**Relationship:** X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Last Name** 

First Name

Middle Name

Cardon, Ph.D.

Lon

**Street Address 1** 

Street Address 2

12230 El Camino Real, Suite 230

City

State/Province/Country

ZIP/PostalCode

San Diego **Relationship:** Executive Officer X Director Promoter

**CALIFORNIA** 

92130

Clarification of Response (if Necessary):

**Last Name First Name** Middle Name Grey Michael **Street Address 1 Street Address 2** 12230 El Camino Real, Suite 230 State/Province/Country ZIP/PostalCode City **CALIFORNIA** 92130 San Diego Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Kordel, Ph.D. Johan **Street Address 1 Street Address 2** 12230 El Camino Real, Suite 230 **State/Province/Country** City ZIP/PostalCode San Diego **CALIFORNIA** 92130 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name** First Name Middle Name Mathers Ed **Street Address 1 Street Address 2** 12230 El Camino Real, Suite 230 City **State/Province/Country** ZIP/PostalCode **CALIFORNIA** San Diego 92130 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name O'Donnell, Ph.D. Niall **Street Address 1 Street Address 2** 12230 El Camino Real, Suite 230 City **State/Province/Country** ZIP/PostalCode San Diego **CALIFORNIA** 92130 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name** First Name Middle Name Johnson Wendy **Street Address 1 Street Address 2** 12230 El Camino Real, Suite 230 City State/Province/Country ZIP/PostalCode San Diego **CALIFORNIA** 92130 Relationship: X Executive Officer Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Dorenbaum, M.D. Alejandro

City State/Province/Country ZIP/PostalCode
San Diego CALIFORNIA 92130

**Street Address 2** 

**Street Address 1** 

12230 El Camino Real, Suite 230

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Harrison Kenneth

Street Address 1 Street Address 2

12230 El Camino Real, Suite 230

City State/Province/Country ZIP/PostalCode

San Diego CALIFORNIA 92130

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Muralidhar Bali

Street Address 1 Street Address 2

12230 El Camino Real, Suite 230

City State/Province/Country ZIP/PostalCode

San Diego CALIFORNIA 92130

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Seltzer Stacey

Street Address 1 Street Address 2

12230 El Camino Real, Suite 230

City State/Province/Country ZIP/PostalCode

San Diego CALIFORNIA 92130

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Cruse Mike

Street Address 1 Street Address 2

12230 El Camino Real, Suite 230

City State/Province/Country ZIP/PostalCode

San Diego CALIFORNIA 92130

**Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Investing

Agriculture Health Care Retailing
Banking & Financial Services Biotechnology Restauran

Commercial Banking
Insurance
Health Insurance
Hospitals & Physicians
Computers

Investment Banking X Pharmaceuticals Telecommunications
Pooled Investment Fund Other Health Care Other Technology

Pooled Investment Fund Other Health Care Other Technology
Is the issuer registered as Manufacturing Travel

an investment company under Real Estate Airlines & Airports

Commercial

Lodging & Conventions the Investment Company Construction Act of 1940? Tourism & Travel Services **REITS & Finance** Yes Other Travel Residential Other Banking & Financial Services Other **Business Services** Other Real Estate Energy **Coal Mining** Electric Utilities **Energy Conservation Environmental Services** Oil & Gas

# 5. Issuer Size

Other Energy

Revenue Range	OR	Aggregate Net Asset Value Range	
No Revenues		No Aggregate Net Asset Value	
\$1 - \$1,000,000		\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000	
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000	
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000	
Over \$100,000,000		Over \$100,000,000	
X Decline to Disclose		Decline to Disclose	
Not Applicable		Not Applicable	

#### 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

## 7. Type of Filing

X New Notice Date of First Sale 2020-12-09 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity
Debt
Ten
Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or
Other Right to Acquire Security
Other

Pooled Investment Fund Interests
Tenant-in-Common Securities
Mineral Property Securities

Other (describe)

#### 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number X None

(Associated) Broker or Dealer CRD X None (Associated) Broker or Dealer X None

Number

**Street Address 1 Street Address 2** 

ZIP/Postal State/Province/Country City Code

State(s) of Solicitation (select all that apply)

A11 Check "All States" or check individual States

States

Foreign/non-US

13. Offering and Sales Amounts

**Total Offering Amount** \$94,769,998 USD or Indefinite

**Total Amount Sold** \$47,384,999 USD

Total Remaining to be Sold \$47,384,999 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15

### 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Reneo Pharmaceuticals, Inc.	/s/ Gregory Flesher	Gregory Flesher	President and CEO	2020-12-18

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.